AbbVie announced that RINVOQ® (upadacitinib) is now approved in the U.S. for treating pediatric patients aged two years and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis…
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high…
Incyte has finalized its acquisition of Escient Pharmaceuticals, a company specializing in the development of small molecule therapeutics for immune and neuro-immune disorders. The acquisition enhances Incyte’s Inflammation and Autoimmunity…
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has released its 2023 Environmental, Social, and Governance (ESG) Report, showcasing significant advancements in sustainable development. Aligned with…
Shionogi & Co., Ltd. recently announced that its subsidiary, Qpex Biopharma, Inc., has exercised a $10 million option granted by the Biomedical Advanced Research and Development Authority (BARDA). This additional…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion,…
Labcorp, a renowned provider of cutting-edge laboratory services globally, is set to unveil multiple abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May…
Today, Astellas announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Biologics License Application (BLA) for zolbetuximab, a groundbreaking investigational monoclonal antibody targeting claudin…
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase…
Today, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for treating…
Today, Pfizer released extended findings from the Phase 3 CROWN trial, examining the efficacy of LORBRENA® (lorlatinib), a third-generation ALK inhibitor, versus XALKORI® (crizotinib) in previously untreated patients with ALK-positive…
The U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory mantle…